MNMartina Nasello

Martina Nasello

*This is an algorithmically generated author record based on publicly available information.

Martina Nasello has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantitative analysis of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies titres: correlation with relapses

    by Martina Nasello, Mark Woodhall, Huiru Xue, Victor Mgbachi, Ruth Geraldes, Maria Isabel Leite, Patrick Waters, Jacqueline Palace

    Detection of antibodies against aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) is essential for diagnosis of AQP4-IgG+ neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Uncertainties persist regarding the clinical significance of serum antibody titres to predict relapses. We aimed to analyse the trend of serum AQP4-IgG and myelin oligodendrocyte glycoprotein antibody-IgG titres during relapses and periods of clinical stability. In this retrospective study we analysed serum AQP4-IgG and myelin oligodendrocyte glycoprotein antibody -IgG titres from live cell-based assays from the Oxford Autoimmune Neurology Diagnostic Laboratory for the UK specialist NMO Service between February 2010 and June 2024. We recruited seropositive AQP4-neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease patients with serum samples available within 30 days of an attack (‘attack’) and at least one another sample for comparison within 1 year (‘pre-attack’ and ‘post-attack’). Up to 3 further serum samples were selected within 2, 3 or 4 years after the attack. 117 attacks in 92 AQP4-IgG+ patients (81.5% female) and 127 attacks in 111 myelin oligodendrocyte glycoprotein antibody-IgG+ patients (62.2% female) had appropriate samples. Antibody titres significantly increased from ‘pre-attack’ to ‘attack’, decreased from ‘attack’ to ‘post-attack’, and remained stable from 2 to 4 years after attacks. Long-term immunosuppressant treatments induced a further decrease in titres during remission in both cohorts. In 40% of samples in both groups there was an increase in titre at relapse. A ≥ 2-fold increase in AQP4-IgG titres had an Odds Ratio (OR) of 6.59% and 91.5% specificity of being associated with a relapse, in myelin oligodendrocyte glycoprotein antibody-IgG+ an OR of 4.87% and 88.6% specificity. 29% (26/92) AQP4-IgG+ patients became ‘seronegative’ during follow: most patients (64%) had low attack titres (≤100), and the time to seroreversion related the attack titre. In contrast, 41% (46/111) myelin oligodendrocyte glycoprotein antibody-IgG+ patients became ‘seronegative’, mostly within the first year after the attack regardless of attack titre. In conclusion, in 60% of longitudinal serum samples from patients with AQP4-IgG or myelin oligodendrocyte glycoprotein antibody-IgG there is no increase in antibody titre. When there is an increase, it is most often at relapse. A ≥ 2-fold increase in titres should be a risk particularly in case of treatment de-escalation, non-adherence to treatment or if a pseudo-relapse is suspected.


  • Open Access

    Gut Microbiota Composition Is Causally Linked to Multiple Sclerosis: A Mendelian Randomization Analysis

    by Valeria Zancan, Martina Nasello, Rachele Bigi, Roberta Reniè, Maria Chiara Buscarinu, Rosella Mechelli, Giovanni Ristori, Marco Salvetti, Gianmarco Bellucci

    Accumulating evidence links the microbial communities inhabiting the gut to the pathophysiological processes underlying multiple sclerosis (MS). However, most studies on the microbiome in MS are correlative in nature, thus being at risk of confounding and reverse causality. Mendelian randomization (MR) analyses allow the estimation of the causal relationship between a risk factor and an outcome of interest using genetic variants as proxies for environmental exposures. Here, we performed a two-sample MR to assess the causality between the gut microbiome and MS. We extracted genetic instruments from summary statistics from three large genome-wide association studies (GWASs) on the gut microbiome (18,340, 8959, and 7738 subjects). The exposure data were derived from the latest GWAS on MS susceptibility (47,429 patients and 68,374 controls). We pinpointed several microbial strains whose abundance is linked with enhanced MS risk (Actinobacteria class, Bifidobacteriaceae family, Lactobacillus genus) or protection (Prevotella spp., Lachnospiranaceae genus, Negativibacillus genus). The largest risk effect was seen for Ruminococcus Torques (OR, 2.89, 95% C.I. 1.67–5, p = 1.51 × 10−4), while Akkermansia municiphila emerged as strongly protective (OR, 0.43, 95% C.I. 0.32–0.57, p = 1.37 × 10−8). Our findings support a causal relationship between the gut microbiome and MS susceptibility, reinforcing the relevance of the microbiome–gut–brain axis in disease etiology, opening wider perspectives on host–environmental interactions for MS prevention.


  • Open Access

    Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience

    by Martina Nasello, Valeria Zancan, Virginia Rinaldi, Antonio Marrone, Roberta Reniè, Selene Diamant, Martina Marconi, Lorenzo Le Mura, Marco Salvetti, Maria Chiara Buscarinu, et al.

    Ocrelizumab (OCR), an anti-CD20 monoclonal antibody, is approved for treating relapsing remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval dosing (SID) regimen requires intravenous infusions every six months. Experience of extended dosing due to COVID-19 pandemic-related issues suggests that this strategy may provide comparable efficacy while reducing treatment burden and healthcare costs. This study aimed to evaluate clinical effectiveness, changes in B- and T-cell count, and immunoglobulin dynamics associated with extended interval dosing (EID) of ocrelizumab in a real-world setting. We retrospectively included RRMS or PPMS patients treated with OCR that had already received two OCR cycles and with at least 6 months of follow up after the last infusion. EID was defined as a ≥4 weeks delay compared to SID. Clinical outcomes were occurrence of relapses, MRI activity, 6-months confirmed disability progression (CDP) and their combination (No Evidence of Disease Activity, NEDA-3). We also evaluated changes in CD19+ B cell count, CD4+ and CD8+ T cell count, immunoglobulin titers, and occurrence of hypogammaglobulinemia (hypo-Ig). Frequency tests, multivariate regression models, and survival analysis were applied as appropriate. We analyzed data on 93 subjects (75.3% RRMS) for a total of 389 infusions (272 SID, 117 EID). Clinical and MRI activity, CDP, and NEDA 3 did not significantly differ between EID and SID. EID was associated with lower rates of B-cell depletion. T-cell dynamics and incidence of hypo-Ig were comparable following EID and SID. Hypo-IgG at index infusion was associated with further occurrence of hypo-IgG; male sex and hypo-IgM at index infusion were independently associated with hypo-IgM. In conclusion, OCR EID does not impact MS clinical and radiological outcomes, although it interferes with B-cell dynamics. These findings provide support for a tailored schedule of OCR in MS.